At Origin, MoCD Type A is our top priority

Origin Biosciences, a subsidiary of BridgeBio Pharma, is an innovative biotechnology company fully dedicated to developing and commercializing a treatment for molybdenum cofactor deficiency (MoCD) Type A. Origin is led by a team of veteran biotechnology executives. Together, with patients and physicians, the company aims to bring a safe, effective treatment for MoCD Type A to market as quickly as possible because time is of the essence when facing the damage caused by this devastating disorder.

Origin Biosciences Leadership Team

Michael joined BridgeBio to bring genetically targeted treatments to those patients with the highest unmet need. He is responsible for identifying and acquiring new technologies and playing a role in both the parent and subsidiary companies. Michael is the CEO of Origin Biosciences and has overseen the creation of 17 companies. He is a voting board member for 5 of BridgeBio’s subsidiary companies and cofounded PellePharm, one of BridgeBio’s portfolio companies, while in medical school. Prior to BridgeBio, Michael consulted for McKinsey & Company’s Silicon Valley Office where he served biotech clients across the US and EU. He received his BA from Harvard University and holds an MD from Stanford University. Originally from Oklahoma, he is a die-hard fan of the Oklahoma Sooners and a sworn enemy of any football team that opposes them.

Carl is passionate about bringing innovative treatments to those in need. This passion led him to a career developing therapies for rare conditions after training as a physician. In addition to practicing medicine, Carl cofounded Novonate, a medical device company focused on reducing neonatal infections, and was an associate at McKinsey & Company. He received his MD and BA from Stanford University, as well as his MA from Columbia University.

Matt joined Origin Biosciences with over 20 years of pharmaceutical/biotech experience, focusing on oncology and various product launches. Before joining Origin, Matt held various leadership positions at Pharmacyclics, including VP of Marketing and Market Access, VP of Commercial Operations, and Chief Commercial Officer. During his time at Pharmacyclics, Matt led the successful launch of Imbruvica for chronic lymphocytic leukemia and spearheaded launches in 5 additional disease states. Matt has also held important roles across marketing, sales, and market access at pharmaceutical and biotech companies including Millennium, Schering Plough, and GlaxoSmithKline. Matt received his BA from Hamilton College, MBA from The University of Delaware, and ALM from Harvard.

Liza began her career in child neurology before transitioning to drug development. She has held senior positions of increasing responsibility at several pharmaceutical companies including Aevi Genomic Medicine, where she focused on the development of therapeutics for CNS disorders and rare conditions in both early and late stage development. She has led and contributed to multiple NDAs and sNDAs, resulting in global regulatory approvals for Topamax® (topiramate), Daytrana® (methylphenidate transdermal system), Vyvanse® (lisdexamfetamine dimesylate) and Intuniv® (guanfacine ER). Liza is the author of many referenced articles in peer-reviewed journals and has been active in advocacy groups for the advancement of pediatric therapeutics. She received her BS from the University of Michigan and MD from Michigan State University.

Raven is the vice president of regulatory affairs at Origin Biosciences and is firmly focused on advancing the development of the company's compound from nonclinical/clinical development through commercialization, ensuring global access for all patients that need it. Most of her regulatory experience has been focused on the treatment of rare diseases in oncology, inborn errors of metabolism, primary immunodeficiency, autoimmune diseases, vaccines, cardiology, and various liver diseases. She joined Origin in 2018 after serving as the head of the regulatory affairs group at Leadiant Biosciences. Prior to that, she worked at ICON Clinical Research and at Nabi Biopharmaceuticals. Raven began her career at the NIH and earned her MS in biotechnology management from the University of Maryland and BS in natural sciences with an emphasis in biology and biophysics from Johns Hopkins University.

Angelos is the senior vice president of technical operations for Origin Biosciences, a BridgeBio company. Throughout his career, Angelos has held positions of increasing responsibility in CMC, preclinical development, manufacturing, quality, program and alliance management, clinical operations and global regulatory affairs. Prior to Origin, he established the CMC and preclinical development functions at Epizyme and served as the head of regulatory affairs. Dr Dovletoglou oversaw the early development work on pinometostat and tazemetostat, cochaired the two JSC teams, achieved key milestones across various functions, and successfully manufactured DS/DP for the clinical studies in the US, EU, and Asia. Prior to Epizyme, Angelos served as a CMC scientist and manager at Biogen, Momenta Pharma, and Merck Research Laboratories contributing to the development, registration, and successful commercial launch of 7 NCEs. Angelos also served as a member of the scientific advisory board at Cocoon Biotech developing novel OA therapies, and chair of the Specifications and BACPAC Working Group at PQRI. He has numerous publications/patents to his name, as well as several therapies on the market that improve the lives of patients. Dr Dovletoglou earned his PhD in inorganic chemistry from the University of North Carolina at Chapel Hill and BS in Chemistry from the University of Athens, Greece. Outside of work, Angelos enjoys time with his family, friends, and riding his fat bike in the snow.

Board of Directors

Neil is the Chief Executive Officer and Founder of BridgeBio Pharma LLC, a company focused on the development of novel therapies for genetic diseases. Prior to founding BridgeBio, he held prominent roles with both established and emerging companies, including Principal at Third Rock Ventures, VP of Business Development and Operations for MyoKardia, and Associate Principal at McKinsey & Company. Additionally, Neil was involved in the formation of a gene chip startup and was a technical consultant for AstraZeneca’s pathway signaling group. Neil is the author of several peer-reviewed papers in the fields of oncology and systems biology. He holds BS and MS degrees in Chemical Engineering from Stanford University, and received his PhD in Chemical Engineering from the Massachusetts Institute of Technology.

Michael joined BridgeBio to bring genetically targeted treatments to those patients with the highest unmet need. He is responsible for identifying and acquiring new technologies and playing a role in both the parent and subsidiary companies. Michael is the CEO of Origin Biosciences and has overseen the creation of 17 companies. He is a voting board member for 5 of BridgeBio’s subsidiary companies and cofounded PellePharm, one of BridgeBio’s portfolio companies, while in medical school. Prior to BridgeBio, Michael consulted for McKinsey & Company’s Silicon Valley Office where he served biotech clients across the US and EU. He received his BA from Harvard University and holds an MD from Stanford University. Originally from Oklahoma, he is a die-hard fan of the Oklahoma Sooners and a sworn enemy of any football team that opposes them.

Daniel, a board member of Origin Biosciences, is currently SVP of BioPharma Business Development at Guardant Health, where he uses Guardant’s digital sequencing platform to focus on partnerships with biopharmaceutical companies across the continuum of care. Daniel brings more than 15 years of experience in the life sciences industry across business development, strategy, and operations. Daniel previously held positions at MyoKardia, Onyx Pharmaceuticals, McKinsey & Company, and Genentech. His academic accomplishments include an MBA from the University of Pennsylvania’s Wharton School and an MA with Honours in Natural Sciences from the University of Cambridge.

ORIGIN IS A MEMBER OF THE BRIDGEBIO FAMILY

BridgeBio is a team of experienced drug discoverers, developers and innovators working to create life-altering medicines that target well-characterized genetic diseases at their source. BridgeBio was founded in 2015 to identify and advance transformative medicines to treat patients who suffer from Mendelian diseases, which are diseases that arise from defects in a single gene, and cancers with clear genetic drivers. BridgeBio’s pipeline of over 20 development programs includes product candidates ranging from early discovery to late-stage development.

bridgebio-hope through rigorous science

San Francisco Office

75 Federal Street
San Francisco, CA 94107
Phone (650) 391.9740

Email info@OriginTX.com

Boston Office

75 Park Plaza
Boston, MA 02116
Phone (650) 391.9740

Email info@OriginTX.com